

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7 SEP 11 WPI DS, WPI INDEX, and WPI X now include Japanese FTERM thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10 OCT 27 Free display of legal status information in CA/CAPLUS, USPATFULL, and USPAT2 in the month of November.

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:56:28 ON 01 NOV 2009

=> file caplus	
COST IN U.S. DOLLARS	SINCE FILE
TOTAL	ENTRY SESSION
FULL ESTIMATED COST	0.22 0.22

FILE 'CAPLUS' ENTERED AT 11:56:49 ON 01 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Nov 2009 VOL 151 ISS 19
FILE LAST UPDATED: 30 Oct 2009 (20091030/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

=> s (tr1 or (tr(w)1))/bi,ab	1096 TR1/B	964
TR1/AB	18848 TR/B	16361 TR/AB
10382861 1/B	9450149 1/AB	825
TR(W)1		
L1	1893 (TR1 OR (TR(W)1))/B,AB	

=> s (cd11a or (cd(w)11a) or cd49b or (cd(w)49b))/bi,ab		
2439 CD11A/B	1951 CD11A/AB	326858
CD/B	270751 CD/AB	10322 11A/B
8701 11A/AB	14 CD(W)11A	158 CD49B/B
142 CD49B/AB	326858 CD/B	270751
CD/AB	105 49B/B	89 49B/AB
1 CD(W)49B		
L2	2586 (CD11A OR (CD(W)11A) OR CD49B OR (CD(W)49B))/B,AB	

=> s l1 and l2
L3
2 L1 AND L2

=> d his
(FILE 'HOME' ENTERED AT 11:56:28 ON 01 NOV 2009)
FILE 'CAPLUS' ENTERED AT 11:56:49 ON 01 NOV 2009
L1
L2
L3
1893 S (TR1 OR (TR(W)1))/B,AB
2586 S (CD11A OR (CD(W)11A) OR CD49B OR (CD(W)49B))/B,AB
2 S L1 AND L2

=> d l3 1-2 bi ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN
AN 2009:1224075 CAPLUS <<LOGINID:20091101>>
TI Increased expression of regulatory ***Tr1*** cells in
recurrent hepatitis C after liver transplantation
AU Carpentier, A.; Conti, F.; Stenard, F.; Aoudjehane, L.;
Mroux, C.; Povedin, P.; Morales, O.; Chouzenoux, S.; Scatton,
O.; Groux, H.; Aurialt, C.; Calmus, Y.; Pancre, V.; Delhem, N.
CS Laboratoire de Biologie Cellulaire, Universite Rene Descartes,
Paris, Fr.
SO American Journal of Transplantation (2009), 9(9), 2102-
2112 CODEN: AJTMBR; ISSN: 1600-6135
PB Wiley-Blackwell
DT Journal
LA English
AB Immune response failure during HCV infection has been
assoc. with the activity of regulatory T cells. Hepatitis C-related
cirrhosis is the main reason for liver transplantation. However,
80% of transplanted patients present an accelerated recurrence
of the disease. This study assessed the involvement of
regulatory T-cell subsets (CD4+CD25+ cells: 'Treg' and
CD49b + CD18+ cells: 'T regulatory-1' cells), in the
recurrence of HCV after liver transplantation, using transcriptomic
anal., ELISA assays on serum samples and immunohistochem. on
liver biopsies from liver recipients 1 and 5 years after
transplantation. Three groups of patients were included: stable
HCV-neg. recipients and those with mild and severe hepatitis C
recurrence. At 5 years, Treg markers were overexpressed in all
HCV+ recipients. By contrast, ***Tr1*** markers were only
overexpressed in patients with severe recurrence. At 1 yr, a
trend toward the overexpression of ***Tr1*** was noted in
patients evolving toward severe recurrence. IL-10 prodn., a
characteristic of the ***Tr1*** subset, was enhanced in
severe recurrence at both 1 and 5 years. These results suggest
that ***Tr1*** are enhanced during severe HCV recurrence
after liver transplantation and could be predictive of HCV
recurrence. High levels of IL-10 at 1 yr could be predictive of
severe recurrence, and high IL-10 producers might warrant more
intensive management.
RE CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE
FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN
AN 2005:618 CAPLUS <<LOGINID:20091101>>
DN 142:73419
TI Method for identification of ***Tr1*** regulator
lymphocytes by the presence and the expression of specific
molecules, and diagnostic and therapeutic applications
IN Groux, Herve
FA Txeil, Fr.
SO Fr. Demande, 89 pp. CODEN: FROXBL
DT Patent
LA French
FAN CNT 1 PATENT NO. KIND DATE APPLICATION
NO. DATE -----

P1	FR 2856700	A1	20041231	FR 2003-7601
	20030624	FR 2856700	B1	20070608 AU 2004251462
A1	20050106	AU 2004-251462		20040624 CA 2529941
A1	20050106	CA 2004-2529941		20040624 WO
	2005000344	A2	20050106	WO 2004-FR1583
	20040624	WO 2005000344	A3	20050609 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1660118 A2 20060531 EP 2004-767439
20040624 EP 1660118 B1 20080409 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK JP 2007520197 T 20070726 JP 2006-516319 20040624 AT 391513 T 20080415 AT 2004-767439 20040624 ES 2305836 T3 20081101 ES 2004-767439 20040624 FRAI FR 2003-7601 A 20030624 WO 2004-FR1583 W 20040624
AB The invention discloses a method for the identification of ***Tr1*** regulator lymphocytes in a biol. sample based on the detn. of the simultaneous presence of CD4, CD18 and/or ***CD11a*** and, if necessary, by the description of a overexpression of genes coding for the mols. CD4, PSGL-1, PECAM-1 and .alpha.V/beta.3. The invention also discloses a method for quantification and a method for diagnosis of autoimmune or inflammatory diseases based on the aforementioned process of identification. The invention further discloses a method for enrichment of ***Tr1*** regulator lymphocytes based on the detn. of the simultaneous presence of these mols. The invention also discloses the use of a compn. so enriched for the treatment by an autoimmune or inflammatory disease, in particular Crohn's disease.
OSC G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his
(FILE 'HOME' ENTERED AT 11:56:28 ON 01 NOV 2009)
FILE 'CAPLUS' ENTERED AT 11:56:49 ON 01 NOV 2009
L1 1893 S (TR1 OR (TR(W)1))/BI/AB
L2 2586 S (CD11A OR (CD(W)11A) OR CD49B OR
(CD(W)49B))/BI/AB
L3 2 S L1 AND L2

=> log y
COST IN U.S. DOLLARS SINCE FILE
TOTAL ENTRY SESSION
FULL ESTIMATED COST 47.32 47.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE
FILE TOTAL ENTRY
SESSION
CA SUBSCRIBER PRICE -1.64 -1.64

STN INTERNATIONAL LOGOFF AT 11:58:06 ON 01 NOV 2009